1-3 of 3
Shuichi Midorikawa
Close
Sort by
Journal Articles

Multicenter Phase II Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia-Lymphoma

Hiroshi Fujiwara, MD PhD, Takashi Ishida, MD PhD, Kisato Nosaka, MD PhD, Naoya Taira, MD, Yasunobu Abe, MD PhD, Yoshitaka Imaizumi, MD PhD, Yukiyoshi Moriuchi, MD, Tatsuro Jo, MD PhD, Kenichi Ishizawa, MD, PhD, Kensei Tobinai, MD PhD, Kunihiro Tsukasaki, MD PhD, Shigeki Ito, MD PhD, Makoto Yoshimitsu, Maki Otsuka, Michinori Ogura, MD, Shuichi Midorikawa, PhD, Wanda Ruiz, PhD, Tomoko Ohtsu, MD
Journal: Blood
Blood (2015) 126 (23): 181.
https://doi.org/10.1182/blood.V126.23.181.181
Published: 2015
Journal Articles

Phase 2 Study of Lenalidomide in Combination with Low-Dose Dexamethasone in Japanese Transplantation-Ineligible Newly-Diagnosed Multiple Myeloma Patients

Takaaki Chou, Atsushi Shinagawa, MD PhD, Toshiki Uchida, MD, Masafumi Taniwaki, MD PhD, Hirokazu Hirata, MD PhD, Kenichi Ishizawa, MD PhD, Kosei Matsue, MD PhD, Yoshiaki Ogawa, MD, Takayuki Shimizu, MD PhD, Maki Otsuka, MD, Morio Matsumoto, MD, Shinsuke Iida, Yasuhito Terui, MD PhD, Itaru Matsumura, Takashi Ikeda, MD PhD, Naoki Takezako, MD PhD, Yumi Ogaki, MD, Shuichi Midorikawa, MD, Vanessa Houck, Annette Ervin-Haynes, Kenshi Suzuki, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3452.
https://doi.org/10.1182/blood.V124.21.3452.3452
Published: 2014
Journal Articles

MM-004: A Phase 1, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, Efficacy, and Pharmacokinetics of Pomalidomide Alone or in Combination with Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma in Japan

Shinsuke Iida, Hiromi Iwasaki, MD PhD, Takaaki Chou, Kensei Tobonai, Kazutaka Sunami, Yoshiaki Ogawa, MD, Mari Kurihara, Shuichi Midorikawa, Mohamed H. Zaki, MD, Thomas Doerr, MSc, Kosei Matsue
Journal: Blood
Blood (2014) 124 (21): 2107.
https://doi.org/10.1182/blood.V124.21.2107.2107
Published: 2014